TY - JOUR
T1 - Outcomes after liver transplantation using deceased after circulatory death donors
T2 - A comparison of outcomes in the UK and the US
AU - Ivanics, Tommy
AU - Claasen, Marco P.A.W.
AU - Patel, Madhukar S.
AU - Giorgakis, Emmanouil
AU - Khorsandi, Shirin E.
AU - Srinivasan, Parthi
AU - Prachalias, Andreas
AU - Menon, Krishna
AU - Jassem, Wayel
AU - Cortes, Miriam
AU - Sayed, Blayne A.
AU - Mathur, Amit K.
AU - Walker, Kate
AU - Taylor, Rhiannon
AU - Heaton, Nigel
AU - Mehta, Neil
AU - Segev, Dorry L.
AU - Massie, Allan B.
AU - van der Meulen, Jan H.P.
AU - Sapisochin, Gonzalo
AU - Wallace, David
N1 - Funding Information:
Gonzalo Sapisochin discloses consultancy for Astra‐Zeneca, Roche, Novartis and Integra. Gonzalo Sapisochin has received financial compensation for talks for Roche, Astra‐Zeneca, Chiesi and Integra. Gonzalo Sapisochin has received a grant from Roche. None of the other authors have any conflicts of interest to declare.
Publisher Copyright:
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
PY - 2023/5
Y1 - 2023/5
N2 - Background and Aims: Identifying international differences in utilization and outcomes of liver transplantation (LT) after donation after circulatory death (DCD) donation provides a unique opportunity for benchmarking and population-level insight. Methods: Adult (≥18 years) LT data between 2008 and 2018 from the UK and US were used to assess mortality and graft failure after DCD LT. We used time-dependent Cox-regression methods to estimate hazard ratios (HR) for risk-adjusted short-term (0–90 days) and longer-term (90 days–5 years) outcomes. Results: One-thousand five-hundred-and-sixty LT receipts from the UK and 3426 from the US were included. Over the study period, the use of DCD livers increased from 15.7% to 23.9% in the UK compared to 5.1% to 7.6% in the US. In the UK, DCD donors were older (UK:51 vs. US:33 years) with longer cold ischaemia time (UK: 437 vs. US: 333 min). Recipients in the US had higher Model for End-stage Liver Disease (MELD) scores, higher body mass index, higher proportions of ascites, encephalopathy, diabetes and previous abdominal surgeries. No difference in the risk-adjusted short-term mortality or graft failure was observed between the countries. In the longer-term (90 days–5 years), the UK had lower mortality and graft failure (adj.mortality HR:UK: 0.63 (95% CI: 0.49–0.80); graft failure HR: UK: 0.72, 95% CI: 0.58–0.91). The cumulative incidence of retransplantation was higher in the UK (5 years: UK: 11.9% vs. 4.6%; p <.001). Conclusions: For those receiving a DCD LT, longer-term post-transplant outcomes in the UK are superior to the US, however, significant differences in recipient illness, graft quality and access to retransplantation were seen between the two countries.
AB - Background and Aims: Identifying international differences in utilization and outcomes of liver transplantation (LT) after donation after circulatory death (DCD) donation provides a unique opportunity for benchmarking and population-level insight. Methods: Adult (≥18 years) LT data between 2008 and 2018 from the UK and US were used to assess mortality and graft failure after DCD LT. We used time-dependent Cox-regression methods to estimate hazard ratios (HR) for risk-adjusted short-term (0–90 days) and longer-term (90 days–5 years) outcomes. Results: One-thousand five-hundred-and-sixty LT receipts from the UK and 3426 from the US were included. Over the study period, the use of DCD livers increased from 15.7% to 23.9% in the UK compared to 5.1% to 7.6% in the US. In the UK, DCD donors were older (UK:51 vs. US:33 years) with longer cold ischaemia time (UK: 437 vs. US: 333 min). Recipients in the US had higher Model for End-stage Liver Disease (MELD) scores, higher body mass index, higher proportions of ascites, encephalopathy, diabetes and previous abdominal surgeries. No difference in the risk-adjusted short-term mortality or graft failure was observed between the countries. In the longer-term (90 days–5 years), the UK had lower mortality and graft failure (adj.mortality HR:UK: 0.63 (95% CI: 0.49–0.80); graft failure HR: UK: 0.72, 95% CI: 0.58–0.91). The cumulative incidence of retransplantation was higher in the UK (5 years: UK: 11.9% vs. 4.6%; p <.001). Conclusions: For those receiving a DCD LT, longer-term post-transplant outcomes in the UK are superior to the US, however, significant differences in recipient illness, graft quality and access to retransplantation were seen between the two countries.
UR - https://www.scopus.com/pages/publications/85148377089
U2 - 10.1111/liv.15537
DO - 10.1111/liv.15537
M3 - Article
C2 - 36737866
AN - SCOPUS:85148377089
SN - 1478-3223
VL - 43
SP - 1107
EP - 1119
JO - Liver International
JF - Liver International
IS - 5
ER -